Research guide for for athletes — mechanisms, protocols, and independent analysis from Compound Review.
Why CJC-1295 Works for Athletic Recovery
CJC-1295 is a GHRH analogue that extends the half-life of endogenous GHRH from minutes to days by binding to albumin via a Drug Affinity Complex (DAC). For athletes, the primary interest is in its ability to amplify GH pulsatility, which supports lean body composition, accelerates connective tissue repair, and improves sleep quality — all relevant to training adaptation and recovery.
CJC-1295 Protocol Options for Athletes
Athletic protocols typically use CJC-1295 with DAC at 1–2 mg once or twice weekly, or CJC-1295 without DAC (Mod GRF 1-29) at 100 mcg 2–3× daily before sleep and pre-workout. Stacking with Ipamorelin (a GHRP) is common to amplify the GH pulse through complementary receptor pathways. Injection timing before sleep maximizes alignment with natural GH release patterns.
CJC-1295 from Purgo Labs
CJC-1295 is not approved for human use and has no completed Phase 3 trials in athletic populations. Evidence is primarily pharmacokinetic (human PK studies confirm GH elevation) and preclinical for tissue repair outcomes. Athletes should note that elevated GH and IGF-1 are detectable and prohibited under WADA anti-doping rules.